The state of the hunt:
- Pfizer/BioNTech asked the U.S. FDA to expand its authorization of their vaccine to adolescents.
- Numerous countries restricted the use of the AstraZeneca/Oxford shot to older people—or discontinued it altogether—even as regulators concluded the benefits outweighed the risks.
- COVAX affirmed that SII’s supply commitments to the initiative remain “legally binding” amid…